- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
JPMorgan Chase Boosts Stake in Cancer Screening Firm GRAIL
The financial giant increases its investment in the biotech company developing early cancer detection technology.
Mar. 28, 2026 at 8:59am
Got story updates? Submit your updates here. ›
JPMorgan Chase & Co. has significantly increased its stake in GRAIL, Inc., a biotechnology company focused on developing a multi-cancer early detection blood test. According to a recent SEC filing, JPMorgan Chase grew its position in GRAIL by 159.1% in the third quarter, now owning about 0.53% of the company's shares.
Why it matters
GRAIL's technology aims to identify more than 50 types of cancer at their earliest stages through a simple blood test, which could revolutionize cancer screening and treatment. JPMorgan's increased investment signals confidence in GRAIL's potential to disrupt the oncology market.
The details
JPMorgan Chase acquired an additional 126,576 shares of GRAIL in the third quarter, bringing its total holdings to 206,120 shares worth $12.2 million. This represents a 159.1% increase in JPMorgan's stake in the company. GRAIL is developing its Galleri multi-cancer early detection test, which analyzes cell-free DNA in the blood to identify cancer signals.
- JPMorgan Chase filed its Q3 2026 13F report on March 28, 2026, disclosing the increased GRAIL stake.
- GRAIL was spun out from Illumina and founded in 2016.
The players
JPMorgan Chase & Co.
A major American multinational investment bank and financial services company.
GRAIL, Inc.
A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test.
What’s next
GRAIL is expected to provide updates on the development and regulatory progress of its Galleri test in the coming quarters. Investors will be closely watching the company's ability to bring this innovative cancer screening technology to market.
The takeaway
JPMorgan's substantial increase in its GRAIL stake underscores the financial industry's growing interest in early cancer detection technologies that could transform healthcare. As GRAIL advances its pioneering blood test, the company's success could have far-reaching implications for the future of cancer diagnosis and treatment.
